AstraZeneca PLC’s plan to turn around performance of Brilinta/Brilique (ticagrelor) in the U.S. is likely to be an uphill battle, considering competition from low cost clopidogrel generics and skepticism in the cardiology community about the North American results in the PLATO pivotal trial, among many other factors.
Approved in the U.S